Cours suspendu

Communiqués Cerevel Therapeutics Holdings, Inc.

Actions

CERE

US15678U1280

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2024			Varia. 5j.	Varia. 1 janv.
44,96 ^USD	+0,74%		-.--%	-

01/08/24	AbbVie finalise l'acquisition de Cerevel Therapeutics	MT
01/08/24	Cerevel Therapeutics Holdings, Inc. annonce des changements au sein de son conseil d'administration	CI

Communiqués

04/04/25	Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.	BU
31/03/25	Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)	BU
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	PR
19/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	AQ
18/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	AQ
08/12/23	CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE	BU
08/12/23	AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn	AQ
06/12/23	AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline	PR
29/11/23	Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease	AQ
08/11/23	Cerevel Therapeutics to Present at Upcoming Investor Conferences	AQ
01/11/23	Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates	AQ
13/10/23	Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023	AQ
12/10/23	Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock	AQ
11/10/23	Cerevel Therapeutics Announces Proposed Public Offering of Common Stock	AQ
29/08/23	Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference	AQ
02/08/23	Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates	AQ
05/07/23	Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023	AQ
15/06/23	Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer	AQ
10/05/23	CEREVEL THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
10/05/23	Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer	AQ
03/05/23	CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
03/05/23	Cerevel Therapeutics : 1Q 2023 Financial Results & Business Update	PU
03/05/23	CEREVEL THERAPEUTICS HOLDINGS, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
03/05/23	Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results	AQ
26/04/23	Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference	AQ